Top

Published in:

Open Access 01-12-2013 | Review

Neoadjuvant treatment of melanoma: case reports and review

Authors: Shachar Laks, Kevin A Brueske, Eddy C Hsueh

Published in: Experimental Hematology & Oncology | Issue 1/2013

Abstract

Neoadjuvant therapy is an under-utilized regimen for the treatment of metastatic melanoma. The use of this approach has been increasing in other tumor types. Neoadjuvant therapy may reduce occult circulating tumor cell burden in the face of bulky disease and afford a real time evaluation of treatment effectiveness. Neoadjuvant approach can also provide preoperative histologic and molecular analysis of treated tissue that may guide the postoperative treatment planning in patients with resectable metastatic melanoma lesions. The putative benefits of better margin control and clearance of occult systemic disease would theoretically improve surgical outcome. With the advent of effective agents against metastatic melanoma, this common approach to the treatment of rectal cancer, metastatic colon cancer, and breast cancer should also be evaluated as a viable treatment strategy for advanced stage melanoma.

Available only for authorised users

Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. Edited by: SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013.

Ekwueme DU, Guy GP, Li C, Rim SH, Parelkar P, Chen SC: The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity - United States, 2000 to 2006. J Am Acad Dermatol 2011,65(5):S133–143.PubMedCrossRef

American Cancer Society: Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013.

Lee B, Mukhi N, Liu D: Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012, 5: 3.PubMedCentralPubMedCrossRef

Sasson HN, Poo WJ, Bakas MH, Ariyan S: Prolonged survival in patients treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg 1996,37(3):286–92.PubMedCrossRef

Jouary T, Legros C, Lalanne N, Versapuech J, Ezzedine K, Vergier B, et al.: Neoadjuvant chemotherapy: a new criterion for selection of candidate patients for surgery of low tumour burden metastases from malignant melanoma? Br J Dermatol 2010, 163: 183–87.PubMed

Shah GD, Socci ND, Gold JS, Wolchok JD, Carvajal RD, Panageas KS, et al.: Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol 2010, 21: 1717–22.CrossRef

Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, et al.: Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998, 8: 549–556.PubMedCrossRef

Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, et al.: A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer 2002, 94: 470–476.PubMedCrossRef

10.

Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al.: Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005, 23: 8057–8064.PubMedCentralPubMedCrossRef

11.

Lewis KD, Robinson WA, McCarter M, Pearlman N, O’Day SJ, Anderson C, et al.: Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 2006, 24: 3157–63.PubMedCrossRef

12.

Kounalakis N, Gao D, Gonzalez R, Becker M, Lewis K, Poust J, et al.: A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy 2012,4(7):679–686.PubMedCrossRef

13.

Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al.: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24: 3164–71.PubMedCrossRef

14.

Serrone L, Zeuli M, Sega FM, Cognetti F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000,19(1):21–34.PubMed

15.

Boddie AW, Cangir A: Adjuvant and neoadjuvant nhemotherapy with dacarbazine in high-risk childhood melanoma. Cancer 1987, 60: 1720–23.PubMedCrossRef

16.

Rietschel P, Wolchok JD, Krown S, Gerst S, Jungbluth AA, Busam K, et al.: Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008, 26: 2299–2304.PubMedCrossRef

17.

Janco JM, Markovic SN, Weaver AL, Cliby WA: Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol 2013,129(20):533–37.PubMedCrossRef

18.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, et al.: A randomized phase III trial of biochemotherapy versus interferon0alpha-2b for adjuvant therapy in patient at high risk for melanoma recurrence. Melanoma Res 2009,19(1):42–9.PubMedCrossRef

19.

Creagan ET, Ahmann DL, Frytak S, Long HJ, Itri LM: Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer 1986, 58: 2576–2578.PubMedCrossRef

20.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–54.PubMedCrossRef

21.

Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al.: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353: 2135–47.PubMedCrossRef

22.

Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al.: RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70: 5518–5527.PubMedCrossRef

23.

Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C: BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008, 6: 751–759.PubMedCrossRef

24.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al.: The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010, 107: 14903–14908.PubMedCentralPubMedCrossRef

25.

Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al.: PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23: 190–200.PubMedCentralPubMedCrossRef

26.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.: BRIM-3 study group. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364: 2507–2516.PubMedCentralPubMedCrossRef

27.

Huang T, Karsy M, Zhuge J, Zhong M, Liu D: B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013, 6: 30.PubMedCentralPubMedCrossRef

28.

Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al.: Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13: 782–9.PubMedCentralPubMedCrossRef

29.

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012,367(18):1694–1703.PubMedCentralPubMedCrossRef

30.

Fadaki N, Cardona-Huerta S, Martineau L, Thummala S, Cheng ST, Bunker SR, et al.: Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep 2012, 22: 2012.

31.

Koers K, Francken AB, Haanen JB, Woerdeman LA, von der Hage JA: Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol 2013,31(16):e251–3.PubMedCrossRef

32.

Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP: Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 2013,31(3):e40–3.PubMedCrossRef

33.

Khattri R, Auger JA, Griffin MD, Sharpe AH, Bluestone JA: Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 1999,162(10):5784–5791.PubMed

34.

Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3: 541–547.PubMedCrossRef

35.

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al.: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270: 985–988.PubMedCrossRef

36.

Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. J Exp Med 1995, 182: 459–465.PubMedCrossRef

37.

Alegre ML, Shiels H, Thompson CB, Gajewski TF: Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998, 161: 3347–3356.PubMed

38.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al.: A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009,15(17):5591–8.PubMedCrossRef

39.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363: 711–723.PubMedCentralPubMedCrossRef

40.

Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al.: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013,369(2):122–33.PubMedCrossRef

41.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al.: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013,369(2):134–44.PubMedCentralPubMedCrossRef

42.

Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE: Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 2013,20(9):3106–11.PubMedCrossRef

43.

Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al.: Pre-operative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial. Clin Cancer Res 2010,16(10):2861–71.PubMedCentralPubMedCrossRef

44.

Tarhini AA, Edington H, Butterfield LH, et al.: neoadjuvant ipilimumab in locally/regionally advanced melanoma: clinical outcome and immune monitoring. J Clin Oncol 2012., 30: (suppl; abstr 8533)

45.

Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al.: Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012,13(6):589–97.PubMedCrossRef

46.

Foote M, Burmeister B, Dwyer P, Burmeister E, Lambie D, Allan C, et al.: An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection. Melanoma Res 2012, 22: 257–262.PubMedCrossRef

47.

Mozzillo N, Caracò C, Mori S, Di Monta G, Botti G, Ascierto PA, et al.: Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med. 2012, 10: 131.PubMedCentralPubMedCrossRef

Title: Neoadjuvant treatment of melanoma: case reports and review
Authors: Shachar Laks
Kevin A Brueske
Eddy C Hsueh
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Experimental Hematology & Oncology / Issue 1/2013
Electronic ISSN: 2162-3619
DOI: https://doi.org/10.1186/2162-3619-2-30

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Three are better than one: plasminogen receptors as cancer theranostic targets

Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Hairy cell leukemia in kidney transplantation: lesson from a rare disorder

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls

Utility of hydroxyurea in mast cell activation syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer